- Michael Aschner, Vanderbilt University
- Phil Biggin, University of Oxford
- Lucio Guido Costa, University of Washington
- David H Farb, Boston University School of Medicine
- Giorgio Palu, University of Padova
- Christopher Morrey, BioMed Central
In this editorial we discuss the views of our Editorial Board Members towards different models of peer review and their experiences with the journal's open peer review policy.
A retrospective cohort study suggests that initiating a higher dose of an antiviral drug for the treatment of herpes zoster is not associated with an increased risk of adverse drug events and supports the safety of these drugs in older adults as part of routine care.
A systematic review suggests there is no evidence for a single mechanism responsible for 5-fluorouracil-induced cardiotoxicity, the underlying mechanisms might be multifactorial and further research is required to elucidate the pathogenesis of this side effect.
Marta Sidoryk-Wegrzynowicz and Michael AschnerBMC Pharmacology and Toxicology 2013, 14:23 (18 April 2013)
BMC Pharmacology and Toxicology 2014, 15:66
News from the web
- 20 December 2014
- FDA: study demonstrates potential for faster drug development
- 19 December 2014
- Test aims to detect dangerous side effects so that fewer patients are given unsafe drugs
- 18 December 2014
- Protein implicated in allergic reactions to medications
- 09 December 2014
- Pricing for new drugs lacks transparency
BMC Pharmacology and Toxicology is an open access, peer-reviewed journal that considers articles on all aspects of chemically defined therapeutic and toxic agents. The journal welcomes submissions from all fields of experimental and clinical pharmacology including clinical trials.
BMC Pharmacology and Toxicology is part of the BMC series which publishes subject-specific journals focused on the needs of individual research communities across all areas of biology and medicine. We offer an efficient, fair and friendly peer review service, and are committed to publishing all sound science, provided that there is some advance in knowledge presented by the work.
BMC series - open, inclusive and trusted.
Section Editor's profile
David H Farb is Professor and Chair of the Department of Pharmacology and Experimental Therapeutics at Boston University School of Medicine. He is Principal Investigator and Director of the Laboratory of Molecular Neurobiology and Director of the university-wide NIGMS training program in Biomolecular Pharmacology. A renowned neuropharmacologist, his research integrates existing electrophysiological, behavioral, pharmacological, and molecular genetic technologies in a novel systems-level platform to establish a molecular dissection of spatial memory. Dr Farb is Section Editor for 'Basic pharmacology' and you can read more about the key issues in this field and his aspirations for the journal in his recent interview here.
"Pharmacology is a powerful interdisciplinary science providing an essential link between hypotheses developed from molecular, systems, and clinical models with the ultimate goal of improving human health. Our journal publishes timely research describing advances in a broad range of disciplines that combine novel approaches within a framework of rigorous scientific research."
BMC series blog
- 19 December 2014
- Sterile Insect Technique- Next Generation Pesticides
- 03 December 2014
- Multiple Sclerosis: Can lifestyle affect depression risk?
- 03 December 2014
- The stress-controlling brain center
BMC Pharmacology and Toxicology assimilated the Editorial boards and history of BMC Pharmacology and BMC Clinical Pharmacology on fusion of the journals in 2012. The full archive of BMC Pharmacology is available from its own archive website, and the objectives and aspirations of the merged journal are explained in the editorial that accompanied the fusion. The full archive of BMC Clinical Pharmacology is available here.